Celltrion Secures Exclusive US Supply Deal, biz.chosun.com Reports

Celltrion Secures Direct Supply Deals with Major US Healthcare Provider and Global Distributor

Celltrion secured exclusive supply agreements with a major US healthcare enterprise for its omalizumab biosimilar Omlyclo and its autoimmune disease treatment Aptozma, according to a report published by biz.chosun.com. The US subsidiary finalized the contracts in early October to supply Omlyclo pre-filled syringe (PFS) formulations and all Aptozma formulations, including intravenous and subcutaneous options.

Omlyclo and Aptozma Join Insurer Preferred Medication Formulary

The US healthcare enterprise party to the agreement operates an integrated delivery network comprising hospitals, an insurance provider, and a pharmacy benefit manager (PBM), as reported by biz.chosun.com. Under the terms of the contract, Omlyclo and Aptozma have been added to the insurer’s formulary as preferred medications and distributed directly to its affiliated medical facilities. Covered members can obtain the therapies through standard physician prescription pathways, ensuring reimbursement eligibility. Celltrion noted that these new agreements build upon existing local supply relationships established through the distribution of its bone health treatments, Stoboclo and Osenvelt, within the same health system’s hospital network.

Commercial Reach Through Retail Pharmacies and Discount Programs

In addition to the integrated healthcare network contract, Omlyclo secured a supply agreement with a major US global distribution enterprise, biz.chosun.com reported. Commercial dispensing began immediately within the distributor’s in-store pharmacies. The product also entered the health insurance channel serving approximately 350,000 employees of the distributing enterprise. Except for select prescriptions requiring vial formulations, Omlyclo was designated as the sole preferred medication over the reference product. The therapy was registered in a drug discount program targeting approximately 74 million members, enabling uninsured patients and their dependents to purchase Omlyclo at reduced prices through retail and partner pharmacies.

Product Name	Reference Biologic	Indication	Formulations
Omlyclo	Xolair (omalizumab)	Chronic Spontaneous Urticaria / Allergic Disease	Pre-Filled Syringe (PFS), Vial
Aptozma	Not specified	Autoimmune Disease	Intravenous (IV), Subcutaneous (SC)

Celltrion Seeks More PBM Agreements to Expand Insurance Coverage

Celltrion is actively engaged in negotiations with multiple large pharmacy benefit managers to secure additional formulary placements for the new products, according to biz.chosun.com. Company executives anticipate finalizing these agreements during the fourth quarter, a development that would expand insurance coverage across the US market. These commercial moves align with the company's strategy to use its US direct sales infrastructure to scale distribution channels, drive prescription volume, and increase the proportion of high-margin product revenues.

Kim Bon-jung, CEO of Celltrion’s US subsidiary, stated that Omlyclo and Aptozma entering the supply channels of major healthcare and distribution enterprises right at launch demonstrates product competitiveness and direct sales execution capabilities. He added that the company intends to convert these confirmed supply contracts into actual prescriptions and revenue growth while swiftly concluding ongoing negotiations with major PBMs, as reported by biz.chosun.com.

References

• Biz.chosun.com.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding any questions about prescription medications or medical conditions.